Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Appetite ; 200: 107540, 2024 Sep 01.
Article in English | MEDLINE | ID: mdl-38852785

ABSTRACT

Chronic pain and obesity frequently occur together. An ideal therapy would alleviate pain without weight gain, and most optimally, could promote weight loss. The neuropeptide neurotensin (Nts) has been separately implicated in reducing weight and pain but could it be a common actionable target for both pain and obesity? Here we review the current knowledge of Nts signaling via its receptors in modulating body weight and pain processing. Evaluating the mechanism by which Nts impacts ingestive behavior, body weight, and analgesia has potential to identify common physiologic mechanisms underlying weight and pain comorbidities, and whether Nts may be common actionable targets for both.


Subject(s)
Chronic Pain , Neurotensin , Obesity , Humans , Chronic Pain/drug therapy , Comorbidity , Animals , Body Weight , Feeding Behavior , Receptors, Neurotensin
2.
Neuropharmacology ; 195: 108639, 2021 09 01.
Article in English | MEDLINE | ID: mdl-34116109

ABSTRACT

Dopamine (DA) neurons in the ventral tegmental area (VTA) modulate physical activity and feeding behaviors that are disrupted in obesity. Yet, the heterogeneity of VTA DA neurons has hindered determination of which ones might be leveraged to support weight loss. We hypothesized that increased activity in the subset of VTA DA neurons expressing neurotensin receptor-1 (NtsR1) might promote weight loss behaviors. To test this, we used Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) to activate VTA NtsR1 neurons in normal weight and diet-induced obese mice. Acute activation of VTA NtsR1 neurons (24hr) significantly decreased body weight in normal weight and obese mice by reducing food intake and increasing physical activity. Moreover, daily activation of VTA NtsR1 neurons in obese mice sustained weight loss over 7 days. Activating VTA NtsR1 neurons also suppressed how much mice worked to obtain sucrose rewards, even when there was high motivation to consume. However, VTA NtsR1 neural activation was not reinforcing, nor did it invoke liabilities associated with whole-body NtsR1 agonism such as anxiety, vasodepressor response or hypothermia. Activating VTA NtsR1 neurons therefore promotes dual behaviors that support weight loss without causing adverse effects, and is worth further exploration for managing obesity.


Subject(s)
Dopaminergic Neurons/metabolism , Receptors, Neurotensin/metabolism , Ventral Tegmental Area/metabolism , Weight Loss/physiology , Animals , Clozapine/analogs & derivatives , Clozapine/pharmacology , Dopaminergic Neurons/drug effects , Mice , Obesity/metabolism , Reward , Ventral Tegmental Area/drug effects , Weight Loss/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...